Fig. 1From: Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experienceLiver function assessed by the ALBI score in patients with no HCC specific treatment compared to patients with different treatment approaches. Patients who did not receive any HCC specific treatment had impaired liver function as shown by a higher ALBI grade. * The group “HCC treatment” includes all patients who received either sorafenib, TACE or a combination of bothBack to article page